A chemotype that inhibits three unrelated pathogenic targets: The botulinum neurotoxin serotype a light chain, P. falciparum malaria, and the Ebola filovirus

Journal of Medicinal Chemistry

Volumn 54, Issue 5, 2011, Pages 1157-1169

  Opsenica, Igor ^a   Burnett, James C ^b   Gussio, Rick ^c   Opsenica, Dejan ^d   Todorović, Nina ^d   Lanteri, Charlotte A ^e   Sciotti, Richard J ^e   Gettayacamin, Montip ^f   Basilico, Nicoletta ^g   Taramelli, Donatella ^g   Nuss, Jonathan E ^h   Wanner, Laura ^h   Panchal, Rekha G ^h   Šolaja, Bogdan A ^a   Bavari, Sina ^h  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF BELGRADE   (Serbia)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^f ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^g UNIVERSITY OF MILAN   (Italy)

^h UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,7 BIS(ALKYLAMINO)DIAZACHRYSENE; 1,7 BIS(AMINOALKYL)DIAZACHRYSENE DERIVATIVE; 1,7 DICHLORO 3,9 DIMETHYLQUINO[8,7H]QUINOLINE; 3,9 DIMETHYL 4,10 DIHYDROQUINO[8,7H]QUINOLINE 1,7 DIONE; 3,9 DIMETHYL N,N' BIS(2 MORPHOLIN 4 YLETHYL)QUINO[8,7H]QUINOLINE 1,7 DIAMINE; 3,9 DIMETHYL N,N' BIS(2 PIPERIDIN 1 YLETHYL)QUINO[8,7H]QUINOLINE 1,7 DIAMINE; 3,9 DIMETHYL N,N' BIS(2 PYRROLIDIN 1 YLETHYL)QUINO[8,7H]QUINOLINE 1,7 DIAMINE; 3,9 DIMETHYL N,N' BIS(3 MORPHOLIN 4 YLPROPYL)QUINO[8,7H]QUINOLINE 1,7 DIAMINE; 3,9 DIMETHYL N,N' BIS(3 PIPERIDIN 1 YLPROPYL)QUINO[8,7H]QUINOLINE 1,7 DIAMINE; 3,9 DIMETHYL N,N' BIS(3 PYRROLIDIN 1 YLPROPYL)QUINO[8,7H]QUINOLINE 1,7 DIAMINE; 4 AMINO 7 CHLOROQUINOLINE; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; BOTULINUM TOXIN A; CHLOROQUINE; DIETHYL (2,2') 3,3' [NAPHTHALENE 1,5 DIYLDI(IMINO)]BISBUT 2 ENOATE; HEMATIN; MEFLOQUINE; METALLOPROTEINASE; N,N' BIS(2 AMINOETHYL) 3,9 DIMETHYLQUINO[8,7H]QUINOLINE 1,7 DIAMINE; N,N' BIS(3 AMINOPROPYL) 3,9 DIMETHYLQUINO[8,7H]QUINOLINE 1,7 DIAMINE; N,N' BIS(4 AMINOBUTYL) 3,9 DIMETHYLQUINO[8,7H]QUINOLINE 1,7 DIAMINE; N,N' BIS[2 (DIETHYLAMINO)ETHYL] 3,9 DIMETHYLQUINO[8,7H]QUINOLINE 1,7 DIAMINE; N,N' BIS[2 (DIMETHYLAMINO)ETHYL] 3,9 DIMETHYLQUINO[8,7H]QUINOLINE 1,7 DIAMINE; N,N' BIS[3 (DIETHYLAMINO)PROPYL] 3,9 DIMETHYLQUINO[8,7H]QUINOLINE 1,7 DIAMINE; N,N' BIS[3 (DIMETHYLAMINO)PROPYL] 3,9 DIMETHYLQUINO[8,7H]QUINOLINE 1,7 DIAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; ANTIPROTOZOAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; EBOLA VIRUS; ENZYME INHIBITION; IC 50; MALARIA FALCIPARUM; MOUSE; NONHUMAN; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; RAT; STRUCTURE ACTIVITY RELATION; VERO CELL;

ANIMALS; ANOPHELES; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; ANTIVIRAL AGENTS; BOTULINUM TOXINS, TYPE A; CELL LINE; CERCOPITHECUS AETHIOPS; CHRYSENES; EBOLAVIRUS; HEMEPROTEINS; MALARIA; MICE; MODELS, MOLECULAR; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; QUINOLINES; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952265619     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100938u     Document Type: Article

References (78)

1. Burnett, J. C.; Henchal, E. A.; Schmaljohn, A. L.; Bavari, S. The evolving field of biodefence: therapeutic developments and diagnostics Nature Rev. Drug Discovery 2005, 4, 281-297 (Pubitemid 41135787)
2. Paddle, B. M. Therapy and prophylaxis of inhaled biological toxins J. Appl. Toxicol. 2003, 23, 139-170 (Pubitemid 36701194)
3. Wein, L. M.; Liu, Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 9984-9989 (Pubitemid 40993679)
4. Willis, B.; Eubanks, L. M.; Dickerson, T. J.; Janda, K. D. The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison Angew. Chem., Int. Ed. Engl. 2008, 47, 8360-8379
5. Emergency Preparedness and Response: Bioterrorism Agents/Diseases; http://emergency.cdc.gov/agent/agentlist-category.asp.
6. Singh, B. R. Intimate details of the most poisonous poison Nature Struct. Biol. 2000, 7, 617-619 (Pubitemid 30636667)
7. Turton, K.; Chaddock, J. A.; Acharya, K. R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility Trends Biochem. Sci. 2002, 27, 552-558 (Pubitemid 35335403)
8. Arnon, S. S.; Schechter, R.; Inglesby, T. V.; Henderson, D. A.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Fine, A. D.; Hauer, J.; Layton, M.; Lillibridge, S.; Osterholm, M. T.; O'Toole, T.; Parker, G.; Perl, T. M.; Russell, P. K.; Swerdlow, D. L.; Tonat, K. Botulinum toxin as a biological weapon: medical and public health management JAMA, J. Am. Med. Assoc. 2001, 285, 1059-1070 (Pubitemid 32176420)
9. Cai, S.; Singh, B. R. Strategies to design inhibitors of Clostridium botulinum neurotoxins Infect. Disord. Drug Targets 2007, 7, 47-57 (Pubitemid 46488260)
10. Binz, T.; Blasi, J.; Yamasaki, S.; Baumeister, A.; Link, E.; Sudhof, T. C.; Jahn, R.; Niemann, H. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins J. Biol. Chem. 1994, 269, 1617-1620 (Pubitemid 24035350)
11. Foran, P. G.; Davletov, B.; Meunier, F. A. Getting muscles moving again after botulinum toxin: novel therapeutic challenges Trends Mol. Med. 2003, 9, 291-299 (Pubitemid 37039963)
12. Foran, P. G.; Mohammed, N.; Lisk, G. O.; Nagwaney, S.; Lawrence, G. W.; Johnson, E.; Smith, L.; Aoki, K. R.; Dolly, J. O. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons J. Biol. Chem. 2003, 278, 1363-1371 (Pubitemid 36790822)
13. Wells, T. N.; Alonso, P. L.; Gutteridge, W. E. New medicines to improve control and contribute to the eradication of malaria Nature Rev. Drug Discovery 2009, 8, 879-891
14. Malaria Foundation International; http://www.malaria.org/.
15. Andriantsoanirina, V.; Ratsimbasoa, A.; Bouchier, C.; Jahevitra, M.; Rabearimanana, S.; Radrianjafy, R.; Andrianaranjaka, V.; Randriantsoa, T.; Rason, M. A.; Tichit, M.; Rabarijaona, L. P.; Mercereau-Puijalon, O.; Durand, R.; Menard, D. Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility Antimicrob. Agents Chemother. 2009, 53, 4588-4597
16. Bonnet, M.; Broek, I.; van Herp, M.; Urrutia, P. P.; van Overmeir, C.; Kyomuhendo, J.; Ndosimao, C. N.; Ashley, E.; Guthmann, J. P. Varying efficacy of artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in vivo studies Malar. J. 2009, 8, 192
17. Dondorp, A. M.; Yeung, S.; White, L.; Nguon, C.; Day, N. P.; Socheat, D.; von Seidlein, L. Artemisinin resistance: current status and scenarios for containment Nature Rev. Microbiol. 2010, 8, 272-280
18. Opsenica, I.; Opsenica, D.; Lanteri, C. A.; Anova, L.; Milhous, W. K.; Smith, K. S.; Šolaja, B. A. New chimeric antimalarials with 4-aminoquinoline moiety linked to a tetraoxane skeleton J. Med. Chem. 2008, 51, 6216-6219
19. Dong, Y.; Wittlin, S.; Sriraghavan, K.; Chollet, J.; Charman, S. A.; Charman, W. N.; Scheurer, C.; Urwyler, H.; Santo Tomas, J.; Snyder, C.; Creek, D. J.; Morizzi, J.; Koltun, M.; Matile, H.; Wang, X.; Padmanilayam, M.; Tang, Y.; Dorn, A.; Brun, R.; Vennerstrom, J. L. The structure-activity relationship of the antimalarial ozonide arterolane (OZ277) J. Med. Chem. 2010, 53, 481-491
20. Cosledan, F.; Fraisse, L.; Pellet, A.; Guillou, F.; Mordmuller, B.; Kremsner, P. G.; Moreno, A.; Mazier, D.; Maffrand, J. P.; Meunier, B. Selection of a trioxaquine as an antimalarial drug candidate Proc. Natl. Acad. Sci. U.S.A 2008, 105, 17579-17584
21. Opsenica, D.; Šolaja, B. A. Antimalarial peroxides J. Serb. Chem. Soc. 2009, 74, 1155-1193 and references therein
22. Barton, V.; Ward, S. A.; Chadwick, J.; Hill, A.; O'Neill, P. M. Rationale design of biotinylated antimalarial endoperoxide carbon centered radical prodrugs for applications in proteomics J. Med. Chem. 2010, 53, 4555-4559
23. Bellot, F.; Cosledan, F.; Vendier, L.; Brocard, J.; Meunier, B.; Robert, A. Trioxaferroquines as new hybrid antimalarial drugs J. Med. Chem. 2010, 53, 4103-4109
24. de Villiers, K. A.; Egan, T. J. Recent advances in the discovery of haem-targeting drugs for malaria and schistosomiasis Molecules 2009, 14, 2868-2887
25. Egan, T. J. Recent advances in understanding the mechanism of hemozoin (malaria pigment) formation J. Inorg. Biochem. 2008, 102, 1288-1299
26. Hastings, I. M.; Bray, P. G.; Ward, S. A. Parasitology. A requiem for chloroquine Science 2002, 298, 74-75
27. Henry, M.; Alibert, S.; Rogier, C.; Barbe, J.; Pradines, B. Inhibition of efflux of quinolines as new therapeutic strategy in malaria Curr. Top. Med. Chem. 2008, 8, 563-578 (Pubitemid 351982580)
28. Cabrera, M.; Paguio, M. F.; Xie, C.; Roepe, P. D. Reduced digestive vacuolar accumulation of chloroquine is not linked to resistance to chloroquine toxicity Biochemistry 2009, 48, 11152-11154
29. Lanteri, C. A.; Johnson, J. D.; Waters, N. C. Recent advances in malaria drug discovery Recent Pat. Anti-infect. Drug Discovery 2007, 2, 95-114 (Pubitemid 46957319)
30. Plouffe, D.; Brinker, A.; McNamara, C.; Henson, K.; Kato, N.; Kuhen, K.; Nagle, A.; Adrian, F.; Matzen, J. T.; Anderson, P.; Nam, T. G.; Gray, N. S.; Chatterjee, A.; Janes, J.; Yan, S. F.; Trager, R.; Caldwell, J. S.; Schultz, P. G.; Zhou, Y.; Winzeler, E. A. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 9059-9064
31. Wu, T.; Nagle, A.; Sakata, T.; Henson, K.; Borboa, R.; Chen, Z.; Kuhen, K.; Plouffe, D.; Winzeler, E.; Adrian, F.; Tuntland, T.; Chang, J.; Simerson, S.; Howard, S.; Ek, J.; Isbell, J.; Deng, X.; Gray, N. S.; Tully, D. C.; Chatterjee, A. K. Cell-based optimization of novel benzamides as potential antimalarial leads Bioorg. Med. Chem. Lett. 2009, 19, 6970-6974
32. Milner, E.; McCalmont, W.; Bhonsle, J.; Caridha, D.; Carroll, D.; Gardner, S.; Gerena, L.; Gettayacamin, M.; Lanteri, C.; Luong, T.; Melendez, V.; Moon, J.; Roncal, N.; Sousa, J.; Tungtaeng, A.; Wipf, P.; Dow, G. Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum Bioorg. Med. Chem. Lett. 2010, 20, 1347-1351
33. Milner, E.; McCalmont, W.; Bhonsle, J.; Caridha, D.; Cobar, J.; Gardner, S.; Gerena, L.; Goodine, D.; Lanteri, C.; Melendez, V.; Roncal, N.; Sousa, J.; Wipf, P.; Dow, G. S. Anti-malarial activity of a nonpiperidine library of next-generation quinoline methanols Malar. J. 2010, 9 (51) 1-10
34. Andrews, S.; Burgess, S. J.; Skaalrud, D.; Kelly, J. X.; Peyton, D. H. Reversal agent and linker variants of reversed chloroquines: activities against Plasmodium falciparum J. Med. Chem. 2010, 53, 916-919
35. October, N.; Watermeyer, N. D.; Yardley, V.; Egan, T. J.; Ncokazi, K.; Chibale, K. Reversed chloroquines based on the 3,4-dihydropyrimidin-2(1 H)-one scaffold: synthesis and evaluation for antimalarial, beta-haematin inhibition, and cytotoxic activity ChemMedChem 2008, 3, 1649-1653
36. Kelly, J. X.; Smilkstein, M. J.; Brun, R.; Wittlin, S.; Cooper, R. A.; Lane, K. D.; Janowsky, A.; Johnson, R. A.; Dodean, R. A.; Winter, R.; Hinrichs, D. J.; Riscoe, M. K. Discovery of dual function acridones as a new antimalarial chemotype Nature 2009, 459, 270-273
37. Musonda, C. C.; Whitlock, G. A.; Witty, M. J.; Brun, R.; Kaiser, M. Chloroquine-astemizole hybrids with potent in vitro and in vivo antiplasmodial activity Bioorg. Med. Chem. Lett. 2009, 19, 481-484
38. Gemma, S.; Campiani, G.; Butini, S.; Joshi, B. P.; Kukreja, G.; Coccone, S. S.; Bernetti, M.; Persico, M.; Nacci, V.; Fiorini, I.; Novellino, E.; Taramelli, D.; Basilico, N.; Parapini, S.; Yardley, V.; Croft, S.; Keller-Maerki, S.; Rottmann, M.; Brun, R.; Coletta, M.; Marini, S.; Guiso, G.; Caccia, S.; Fattorusso, C. Combining 4-aminoquinoline- and clotrimazole-based pharmacophores toward innovative and potent hybrid antimalarials J. Med. Chem. 2009, 52, 502-513
39. Iwaniuk, D. P.; Whetmore, E. D.; Rosa, N.; Ekoue-Kovi, K.; Alumasa, J.; de Dios, A. C.; Roepe, P. D.; Wolf, C. Synthesis and antimalarial activity of new chloroquine analogues carrying a multifunctional linear side chain Bioorg. Med. Chem. 2009, 17, 6560-6566
40. Blackie, M. A.; Yardley, V.; Chibale, K. Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo Bioorg. Med. Chem. Lett. 2010, 20, 1078-1080
41. Guetzoyan, L.; Yu, X. M.; Ramiandrasoa, F.; Pethe, S.; Rogier, C.; Pradines, B.; Cresteil, T.; Perree-Fauvet, M.; Mahy, J. P. Antimalarial acridines: synthesis, in vitro activity against P. falciparum and interaction with hematin Bioorg. Med. Chem. 2009, 17, 8032-8039
42. Bausch, D. G.; Towner, J. S.; Dowell, S. F.; Kaducu, F.; Lukwiya, M.; Sanchez, A.; Nichol, S. T.; Ksiazek, T. G.; Rollin, P. E. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites J. Infect. Dis. 2007, 196 (Suppl 2) S142-S147
43. Kuhn, J. H. Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies Arch. Virol. Suppl. 2008, 20, 13-360
44. Health Topics: Haemorrhagic Fevers, Viral; World Health Organization: Geneva; http://www.who.int/topics/haemorrhagic-fevers-viral/en/.
45. Aman, M. J.; Kinch, M. S.; Warfield, K.; Warren, T.; Yunus, A.; Enterlein, S.; Stavale, E.; Wang, P.; Chang, S.; Tang, Q.; Porter, K.; Goldblatt, M.; Bavari, S. Development of a broad-spectrum antiviral with activity against Ebola virus Antiviral Res. 2009, 83, 245-251
46. Gunther, S.; Asper, M.; Roser, C.; Luna, L. K.; Drosten, C.; Becker-Ziaja, B.; Borowski, P.; Chen, H. M.; Hosmane, R. S. Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro Antiviral Res. 2004, 63, 209-215 (Pubitemid 39286758)
47. Warren, T. K.; Warfield, K. L.; Wells, J.; Enterlein, S.; Smith, M.; Ruthel, G.; Yunus, A. S.; Kinch, M. S.; Goldblatt, M.; Aman, M. J.; Bavari, S. Antiviral activity of a small-molecule inhibitor of filovirus infection Antimicrob. Agents Chemother. 2010, 54, 2152-2159
48. Chong, C. R.; Sullivan, D. J., Jr. New uses for old drugs Nature 2007, 448, 645-646 (Pubitemid 47236844)
49. Sundar, S.; Jha, T. K.; Thakur, C. P.; Engel, J.; Sindermann, H.; Fischer, C.; Junge, K.; Bryceson, A.; Berman, J. Oral miltefosine for Indian visceral leishmaniasis N. Engl. J. Med. 2002, 347, 1739-1746 (Pubitemid 35375612)
50. Shen, Y.; Zhukovskaya, N L.; Zimmer, M. I.; Soelaiman, S.; Bergson, P.; Wang, C. R.; Gibbs, C. S.; Tang, W. J. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection Proc. Natl. Acad. Sci. U.S.A 2004, 101, 3242-3247 (Pubitemid 38327765)
51. Burnett, J. C.; Schmidt, J. J.; Stafford, R. G.; Panchal, R. G.; Nguyen, T. L.; Hermone, A. R.; Vennerstrom, J. L.; McGrath, C. F.; Lane, D. J.; Sausville, E. A.; Zaharevitz, D. W.; Gussio, R.; Bavari, S. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity Biochem. Biophys. Res. Commun. 2003, 310, 84-93 (Pubitemid 37162766)
52. Burnett, J. C.; Ruthel, G.; Stegmann, C. M.; Panchal, R. G.; Nguyen, T. L.; Hermone, A. R.; Stafford, R. G.; Lane, D. J.; Kenny, T. A.; McGrath, C. F.; Wipf, P.; Stahl, A. M.; Schmidt, J. J.; Gussio, R.; Brunger, A. T.; Bavari, S. Inhibition of metalloprotease botulinum serotype A from a pseudopeptide binding mode to a small molecule that is active in primary neurons J. Biol. Chem. 2007, 282, 5004-5014 (Pubitemid 47100957)
53. Burnett, J. C.; Opsenica, D.; Sriraghavan, K.; Panchal, R. G.; Ruthel, G.; Hermone, A. R.; Nguyen, T. L.; Kenny, T. A.; Lane, D. J.; McGrath, C. F.; Schmidt, J. J.; Vennerstrom, J. L.; Gussio, R.; Šolaja, B. A.; Bavari, S. A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease J. Med. Chem. 2007, 50, 2127-2136 (Pubitemid 46683065)
54. Šolaja, B. A.; Opsenica, D.; Smith, K. S.; Milhous, W. K.; Terzic, N.; Opsenica, I.; Burnett, J. C.; Nuss, J.; Gussio, R.; Bavari, S. Novel 4-aminoquinolines active against chloroquine-resistant and sensitive P. falciparum strains that also inhibit botulinum serotype A J. Med. Chem. 2008, 51, 4388-4391
55. Hermone, A. R.; Burnett, J. C.; Nuss, J. E.; Tressler, L. E.; Nguyen, T. L.; Šolaja, B. A.; Vennerstrom, J. L.; Schmidt, J. J.; Wipf, P.; Bavari, S.; Gussio, R. Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore ChemMedChem 2008, 3, 1905-1912
56. Schmidt, J. J.; Bostian, K. A. Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin J. Protein Chem. 1997, 16, 19-26 (Pubitemid 27114001)
57. Schmidt, J. J.; Bostian, K. A. Proteolysis of synthetic peptides by type A botulinum neurotoxin J. Protein Chem. 1995, 14, 703-708 (Pubitemid 26006119)
58. Schmidt, J. J.; Stafford, R. G. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F Appl. Environ. Microbiol. 2003, 69, 297-303 (Pubitemid 36077488)
59. Schmidt, J. J.; Stafford, R. G. A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity FEBS Lett. 2002, 532, 423-426 (Pubitemid 35441386)
60. Schmidt, J. J.; Stafford, R. G.; Bostian, K. A. Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1′ binding subsite FEBS Lett. 1998, 435, 61-64 (Pubitemid 28432015)
61. Schmidt, J. J.; Stafford, R. G.; Millard, C. B. High-throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F Anal. Biochem. 2001, 296, 130-137 (Pubitemid 32808404)
62. Burnett, J. C.; Wang, C.; Nuss, J. E.; Nguyen, T. L.; Hermone, A. R.; Schmidt, J. J.; Gussio, R.; Wipf, P.; Bavari, S. Pharmacophore-guided lead optimization: the rational design of a non-zinc coordinating, submicromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease Bioorg. Med. Chem. Lett. 2009, 19, 5811-5813
63. Opsenica, D.; Pocsfalvi, G.; Juranic, Z.; Tinant, B.; Declercq, J. P.; Kyle, D. E.; Milhous, W. K.; Šolaja, B. A. Cholic acid derivatives as 1,2,4,5-tetraoxane carriers: structure and antimalarial and antiproliferative activity J. Med. Chem. 2000, 43, 3274-3282
64. Parapini, S.; Basilico, N.; Pasini, E.; Egan, T. J.; Olliaro, P.; Taramelli, D.; Monti, D. Standardization of the physicochemical parameters to assess in vitro the beta-hematin inhibitory activity of antimalarial drugs Exp. Parasitol. 2000, 96, 249-256 (Pubitemid 32195402)
65. Yamada, K.; Hakura, A.; Kato, T. A.; Mizutani, T.; Saeki, K. Nitrogen-substitution effects on the mutagenicity and cytochrome P450 isoform-selectivity of chrysene analogs Mutat. Res. 2005, 586, 87-95 (Pubitemid 41133441)
66. Toxicological Profile For Polycyclic Aromatic Hydrocarbons. U.S. Department of Health and Human Services. Public Health Service Agency for Toxic Substances and Disease Registry: Atlanta, GA, 1995; http://www.atsdr.cdc.gov/ toxprofiles/tp69.html.
67. 99 (reflects MIC and full efficacy, however, based on a relatively small number of surviving parasites available for analysis).
68. Developmental Therapeutics Program; National Cancer Institute: Bethesda, MD (NCI); http://dtp.nci.nih.gov.
69. Opsenica, I.; Terzic, N.; Opsenica, D.; Angelovski, G.; Lehnig, M.; Eilbracht, P.; Tinant, B.; Juranic, Z.; Smith, K. S.; Yang, Y. S.; Diaz, D. S.; Smith, P. L.; Milhous, W. K.; Dokovic, D.; Šolaja, B. A. Tetraoxane antimalarials and their reaction with Fe(II) J. Med. Chem. 2006, 49, 3790-3799 (Pubitemid 43970709)
70. Stable compounds were defined as having half-lives of >60 min.
71. Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique Antimicrob. Agents Chemother. 1979, 16, 710-718 (Pubitemid 10082023)
72. Milhous, W. K.; Weatherly, N. F.; Bowdre, J. H.; Desjardins, R. E. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs Antimicrob. Agents Chemother. 1985, 27, 525-30 (Pubitemid 15097653)
73. Towner, J. S.; Paragas, J.; Dover, J. E.; Gupta, M.; Goldsmith, C. S.; Huggins, J. W.; Nichol, S. T. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening Virology 2005, 332, 20-27 (Pubitemid 40127226)
74. Moe, J. B.; Lambert, R. D.; Lupton, H. W. Plaque assay for Ebola virus J. Clin. Microbiol. 1981, 13, 791-793 (Pubitemid 11047571)
75. Panchal, R. G.; Kota, K. P.; Spurgers, K. B.; Ruthel, G.; Tran, J. P.; Boltz, R. C.; Bavari, S. Development of High-Content Imaging Assays for Lethal Viral Pathogens J. Biomol. Screen. 2010, 15, 755-765
76. Gettayacamin, M.; Sattabongkot, J.; Hansukjariya, P.; Tungtaeng, A.; Kyle, D. Development of Anopheles dirus Sporozoite-Induced Mouse Malaria Model Am. J. Trop. Med. Hyg. 2006, 75 (5S) 156-157
77. Chen, B. J.; Lamb, R. A. Mechanisms for enveloped virus budding: Can some viruses do without ESCRT? Virology 2008, 371, 221-232
78. Dow, G. S.; Caridha, D.; Yourick, D.; Cabezas, M.; Wolf, L.; Hudson, T. H. Mefloquine-induced disruption of calcium homeostasis in mammalian cells is similar to that induced by ionomycin Antimicrob. Agents Chemother. 2008, 52, 684-693 (Pubitemid 351170845)